Lessons from oncology to understand and treat pulmonary hypertension

International Journal of Clinical Practice

Volumn 61, Issue SUPPL. 158, 2007, Pages 19-25

  Adnot, S ^a,b   Eddahibi, S ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER INVASION; CARCINOGENESIS; CELL DIVISION; ENDOTHELIUM CELL; HUMAN; METASTASIS; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TUMOR;

EID: 37249059051     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01618.x     Document Type: Review

References (32)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004 351 : 1425 36.
2. Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001 108 : 1141 50.
3. Marcos E, Fadel E, Sanchez O et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004 94 : 1263 70.
4. Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res 2006 98 : 209 17.
5. Zhang S, Fantozzi I, Tigno DD et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003 285 : L740 54.
6. McMurtry MS, Archer SL, Altieri DC et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005 115 : 1479 91.
7. Adnot S. Lessons learned from cancer may help in the treatment of pulmonary hypertension. J Clin Invest 2005 115 : 1461 3.
8. Schermuly RT, Dony E, Ghofrani HA et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005 115 : 2811 21.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 : 57 70.
10. Medema RH, Bos JL. The role of p21ras in receptor tyrosine kinase signaling. Crit Rev Oncog 1993 4 : 615 61.
11. Edgar AJ, Chacon MR, Bishop AE, Yacoub MH, Polak JM. Upregulated genes in sporadic, idiopathic pulmonary arterial hypertension. Respir Res 2006 7 : 1.
12. Jones P, Cowan K, Rabinovitch M. Tenascin-C, proliferation and subendothelial accumulation of fibronectin in progressive pulmonary vascular disease. Am J Pathol 1997 150 : 1349 60.
13. Cowan K, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000 6 : 698 702.
14. Eddahibi S, Guignabert C, Barlier-Mur AM et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 2006 113 : 1857 64.
15. Humbert M, Monti G, Brenot F et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995 151 : 1628 31.
16. Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990 63 : 245 7.
17. Morrell NW. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling Proc Am Thorac Soc 2006 3 : 680 6.
18. Atkinson C, Stewart S, Upton PD et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002 105 : 1672 8.
19. Murray F, Patel HH, Suda RY et al. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am J Physiol Lung Cell Mol Physiol 2007 292 : L294 303.
20. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005 5 : 876 85.
21. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003 3 : 46 54.
22. Michelakis ED, McMurtry MS, Wu XC et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002 105 : 244 50.
23. Taraseviciene-Stewart L, Kasahara Y, Alger L et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. Faseb J 2001 15 : 427 38.
24. Michelakis ED. Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implications. Circ Res 2006 98 : 172 5.
25. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005 120 : 513 22.
26. Mathon NF, Lloyd AC. Cell senescence and cancer. Nat Rev Cancer 2001 1 : 203 13.
27. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965 37 : 614 36.
28. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990 345 : 458 60.
29. Artandi SE, DePinho RA. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 2000 10 : 39 46.
30. Campisi J. Suppressing cancer: the importance of being senescent. Science 2005 309 : 886 7.
31. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001 88 : E2 E11.
32. Eddahibi S, Humbert M, Sediame S et al. Imbalance between platelet VEGF and PDGF in pulmonary hypertension, effects of prostacyclin infusion. Am J Respir Crit Care Med 2000 162 : 1493 9.